London, Jan 25, 2026, 09:33 GMT — Market closed
- Smith & Nephew shares fell 0.8% on Friday, with UK markets shut for the weekend
- A recent filing showed CEO Deepak Nath and other top executives buying U.S.-listed depositary shares.
- Investors are focused on the upcoming full-year results and guidance update scheduled for March 2
Shares in Smith & Nephew SN.L dropped 0.8% on Friday, ending the day at 1,225.5 pence. The FTSE 100 medical-device company’s market value is hovering around £10.4 billion.
Monday’s open may seem calm at first glance, but there’s plenty brewing. Investors are parsing a director-deal disclosure, weighing a fresh sports-medicine acquisition, and gearing up for an earnings report that might shift 2026 projections.
Risk appetite wavered Friday as the FTSE 100 slipped 0.07%, ending the week lower. Investors weighed new geopolitical frictions after the U.S. issued tariff warnings, Reuters reported.
A filing on Friday showed CEO Deepak Nath and three top execs bought American Depositary Shares (ADS) on Jan. 16 via the company’s Employee Stock Purchase Plan, paying $25.90 each. Nath picked up about 410 ADS, the document said, with Craig Gaffin, Paul Connolly, and Scott Schaffner snapping up smaller amounts.
ADS are U.S.-listed certificates that stand for shares in foreign companies, and the “PDMR” label in the notice identifies senior insiders whose transactions must be disclosed under UK market-abuse rules. These trades are typically routine but tend to attract attention as a stock nears its earnings release.
Smith & Nephew made a move on Jan. 21, finalizing its acquisition of Integrity Orthopaedics, the early-stage developer behind the Tendon Seam rotator cuff repair system. The device has U.S. 510(k) clearance, allowing it to be marketed based on its similarity to an existing product, per FDA rules. “Surgeons and patients deserve a rotator cuff repair solution that delivers results they can count on,” said Christie Van Geffen, senior vice president at Smith & Nephew, in the company’s statement. Smith & Nephew
Smith & Nephew announced on Jan. 12 that it agreed to acquire Integrity in a deal worth up to $450 million. The firm will hand over $225 million up front, while the remainder depends on performance targets set for the next five years. The acquisition will be funded using the company’s existing cash reserves.
With its focus on sports medicine, the company faces stiff competition in a crowded U.S. orthopaedics market. Major players are locked in battles for surgeons’ loyalty and hospital spending, centering on evidence, pricing strategies, and bundling products into bigger contracts.
The next key date for Smith & Nephew is March 2, when it will report its fourth-quarter and full-year results. The company intends to provide an update on its 2026 full-year guidance at the same time.
Risks are evident. Should scaling the new shoulder-repair technology stall, or hospitals tighten price controls, management’s margin story could unravel. The broader macro backdrop matters too: demand for elective procedures may hold steady—until it abruptly declines.
